| UniProt ID | PEBB_HUMAN | |
|---|---|---|
| UniProt AC | Q13951 | |
| Protein Name | Core-binding factor subunit beta | |
| Gene Name | CBFB | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 182 | |
| Subcellular Localization | Nucleus . | |
| Protein Description | Forms the heterodimeric complex core-binding factor (CBF) with RUNX family proteins (RUNX1, RUNX2, and RUNX3). RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation.. | |
| Protein Sequence | MPRVVPDQRSKFENEEFFRKLSRECEIKYTGFRDRPHEERQARFQNACRDGRSEIAFVATGTNLSLQFFPASWQGEQRQTPSREYVDLEREAGKVYLKAPMILNGVCVIWKGWIDLQRLDGMGCLEFDEERAQQEDALAQQAFEEARRRTREFEDRDRSHREEMEVRVSQLLAVTGKKTTRP | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 11 | Ubiquitination | VVPDQRSKFENEEFF CCCCCHHHCCCHHHH | 59.91 | 19608861 | |
| 11 | Acetylation | VVPDQRSKFENEEFF CCCCCHHHCCCHHHH | 59.91 | 23749302 | |
| 19 | Methylation | FENEEFFRKLSRECE CCCHHHHHHHHHHCC | 44.31 | - | |
| 25 | S-nitrosylation | FRKLSRECEIKYTGF HHHHHHHCCCEECCC | 6.78 | 24105792 | |
| 28 | Ubiquitination | LSRECEIKYTGFRDR HHHHCCCEECCCCCC | 17.92 | 22053931 | |
| 28 | Acetylation | LSRECEIKYTGFRDR HHHHCCCEECCCCCC | 17.92 | 23749302 | |
| 80 (in isoform 2) | Phosphorylation | - | 25.97 | 24719451 | |
| 80 | Phosphorylation | WQGEQRQTPSREYVD CCCCCCCCCCCCCCH | 25.97 | 30108239 | |
| 82 | Phosphorylation | GEQRQTPSREYVDLE CCCCCCCCCCCCHHH | 40.92 | 28796482 | |
| 85 | Phosphorylation | RQTPSREYVDLEREA CCCCCCCCCHHHHHC | 9.73 | 28796482 | |
| 94 | Ubiquitination | DLEREAGKVYLKAPM HHHHHCCCEEEECCE | 34.45 | - | |
| 96 | Phosphorylation | EREAGKVYLKAPMIL HHHCCCEEEECCEEE | 13.13 | 29496907 | |
| 122 | Sulfoxidation | DLQRLDGMGCLEFDE EHHHCCCCCCEECCH | 3.23 | 21406390 | |
| 150 | Phosphorylation | FEEARRRTREFEDRD HHHHHHHHHHHHHHC | 32.51 | 28555341 | |
| 150 (in isoform 2) | Phosphorylation | - | 32.51 | - | |
| 159 | Phosphorylation | EFEDRDRSHREEMEV HHHHHCCHHHHHHHH | 31.05 | 28985074 | |
| 159 (in isoform 2) | Phosphorylation | - | 31.05 | 22210691 | |
| 169 | Phosphorylation | EEMEVRVSQLLAVTG HHHHHHHHHHHHHHC | 12.44 | 23312004 | |
| 169 | O-linked_Glycosylation | EEMEVRVSQLLAVTG HHHHHHHHHHHHHHC | 12.44 | 28510447 | |
| 173 (in isoform 2) | Phosphorylation | - | 12.86 | 23927012 | |
| 175 | Phosphorylation | VSQLLAVTGKKTTRP HHHHHHHHCCCCCCC | 37.36 | 28555341 | |
| 176 (in isoform 2) | Phosphorylation | - | 23.90 | 23927012 | |
| 177 | Ubiquitination | QLLAVTGKKTTRP-- HHHHHHCCCCCCC-- | 37.27 | - | |
| 177 | Acetylation | QLLAVTGKKTTRP-- HHHHHHCCCCCCC-- | 37.27 | 23749302 | |
| 178 | Ubiquitination | LLAVTGKKTTRP--- HHHHHCCCCCCC--- | 57.37 | - | |
| 185 (in isoform 2) | Ubiquitination | - | - |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of PEBB_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of PEBB_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PEBB_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| SCG1_HUMAN | CHGB | physical | 16169070 | |
| MYOD1_HUMAN | MYOD1 | physical | 20195544 | |
| RUNX1_HUMAN | RUNX1 | physical | 20195544 | |
| RAB2A_HUMAN | RAB2A | physical | 20195357 | |
| VIF_HV1B1 | vif | physical | 24390320 | |
| VIF_HV1BR | vif | physical | 24390320 | |
| VIF_HV1H2 | vif | physical | 24390320 | |
| CUL5_HUMAN | CUL5 | physical | 24402281 | |
| VIF_HV1B1 | vif | physical | 22479405 | |
| VIF_HV1BR | vif | physical | 22479405 | |
| VIF_HV1H2 | vif | physical | 22479405 | |
| VIF_HV1B1 | vif | physical | 23333304 | |
| VIF_HV1BR | vif | physical | 23333304 | |
| VIF_HV1H2 | vif | physical | 23333304 | |
| ELOC_HUMAN | TCEB1 | physical | 23333304 | |
| ELOB_HUMAN | TCEB2 | physical | 23333304 | |
| RUNX1_HUMAN | RUNX1 | physical | 23333304 | |
| RUNX2_HUMAN | RUNX2 | physical | 23333304 | |
| RUNX3_HUMAN | RUNX3 | physical | 23333304 | |
| CRIP1_HUMAN | CRIP1 | physical | 26344197 | |
| GALK1_HUMAN | GALK1 | physical | 26344197 | |
| PPIA_HUMAN | PPIA | physical | 26344197 | |
| SODC_HUMAN | SOD1 | physical | 26344197 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-11, AND MASS SPECTROMETRY. | |